At Reata Pharmaceuticals, our mission is to develop innovative therapies that change patients’ lives for the better.
Reata’s development programs now have an approved product in addition to creating a robust pipeline of drug candidates for the treatment of serious, life-threatening diseases. Find out more here.
aSKYCLARYS (omaveloxolone) is approved by the U.S. FDA and not approved by any other regulatory authority outside the U.S. bMarketing Authorisation Application (MAA) submitted in 4Q22 in Europe. cDiabetic peripheral neuropathic pain (DPNP). Reata plans to initiate a Phase 2 trial of Cemdomespib in patients with DPNP in the third quarter of 2023.
Cemdomespib, RTA 415, and RTA 417 are investigational drugs. Safety and efficacy have not been established by any agency.
We are a team of problem solvers, trailblazers, and people who want to make a difference.